The Persistent Sodium Current Blocker Riluzole Is Antiarrhythmic and Anti-Ischaemic in a Pig Model of Acute Myocardial Infarction

PLoS ONE

Volumn 5, Issue 11, 2010, Pages

  Weiss, Steven M ^a   Saint, David A ^b  

^a AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

LIDOCAINE; RILUZOLE; ANTIARRHYTHMIC AGENT; NEUROPROTECTIVE AGENT; SODIUM CHANNEL BLOCKING AGENT;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIARRHYTHMIC ACTIVITY; ARRHYTHMOGENESIS; ARTICLE; CARDIOVASCULAR RESPONSE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; ELECTROCARDIOGRAM; FEMALE; HEART ARRHYTHMIA; HEART PROTECTION; HISTOLOGY; MALE; NONHUMAN; QRS COMPLEX; ANIMAL; DRUG EFFECT; ELECTROCARDIOGRAPHY; HEART; HEART INFARCTION; HEART MUSCLE; HEART MUSCLE ISCHEMIA; PATHOLOGY; PATHOPHYSIOLOGY; SWINE;

PIERIS BRASSICAE; SUIDAE;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; ELECTROCARDIOGRAPHY; FEMALE; HEART; LIDOCAINE; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIUM; NEUROPROTECTIVE AGENTS; RILUZOLE; SODIUM CHANNEL BLOCKERS; SWINE;

EID: 78649647050     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014103     Document Type: Article

References (39)

1. Clements-Jewery H, Hearse DJ, Curtis MJ (2005) Phase 2 ventricular arrhythmias in acute myocardial infarction: a neglected target for therapeutic antiarrhythmic drug development and for safety pharmacology evaluation. Br J Pharmacol 145: 551-564.
2. Pratt CM, Camm AJ, Cooper W, Friedman PL, MacNeil DJ, et al. (1998) Mortality in the Survival With ORal D-sotalol (SWORD) trial: why did patients die? Am J Cardiol 81: 869-876.
3. Saint DA (2008) The cardiac persistent sodium current: an appealing therapeutic target? Br J Pharmacol 153: 1133-1142.
4. Vacher B, Pignier C, Letienne R, Verscheure Y, Le Grand B (2009) F 15845 inhibits persistent sodium current in the heart and prevents angina in animal models. Br J Pharmacol 156: 214-225.
5. Bae HJ, Lee YS, Kang DW, Koo JS, Yoon BW, et al. (2000) Neuroprotective effect of low dose riluzole in gerbil model of transient global ischemia. Neurosci Lett 294: 29-32.
6. Baptiste DC, Fehlings MG (2006) Pharmacological approaches to repair the injured spinal cord. J Neurotrauma 23: 318-334.
7. Heurteaux C, Laigle C, Blondeau N, Jarretou G, Lazdunski M (2006) Alphalinolenic acid and riluzole treatment confer cerebral protection and improve survival after focal brain ischemia. Neuroscience 137: 241-251.
8. Bryson HM, Fulton B, Benfield P (1996) Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis. Drugs 52: 549-563.
9. Lamanauskas N, Nistri A (2008) Riluzole blocks persistent Na+ and Ca2+ currents and modulates release of glutamate via presynaptic NMDA receptors on neonatal rat hypoglossal motoneurons in vitro. Eur J Neurosci 27: 2501-2514.
10. Ates O, Cayli SR, Gurses I, Turkoz Y, Tarim O, et al. (2007) Comparative neuroprotective effect of sodium channel blockers after experimental spinal cord injury. J Clin Neurosci 14: 658-665.
11. Weiss S, Benoist D, White E, Teng W, Saint DA (2010) Riluzole protects against cardiac ischaemia and reperfusion damage via block of the persistent sodium current. British Journal of Pharmacology 160: 1072-1082.
12. Walker MJ, Curtis MJ, Hearse DJ, Campbell RW, Janse MJ, et al. (1988) The Lambeth Conventions: guidelines for the study of arrhythmias in ischaemia infarction, and reperfusion. Cardiovasc Res 22: 447-455.
13. Cascio WE, Yang H, Muller-Borer BJ, Johnson TA (2005) Ischemia-induced arrhythmia: the role of connexins, gap junctions, and attendant changes in impulse propagation. J Electrocardiol 38: 55-59.
14. Curtis MJ (1998) Characterisation, utilisation and clinical relevance of isolated perfused heart models of ischaemia-induced ventricular fibrillation. Cardiovasc Res 39: 194-215.
15. Meesmann W (1982) Early arrhythmias and primary ventricular fibrillation after acute myocardial ischaemia in relation to pre-existing coronary collaterals. Early Arrhythmias Resulting from Myocardial Ischaemia, Parrat JR, ed. London: McMillan. pp 93-112.
16. Pugsley MK, Ries CR, Guppy LJ, Harvie CJ, Walker MJ (1995) Effects of anipamil, a long acting analog of verapamil, in pigs subjected to myocardial ischemia. Life Sci 57: 1219-1231.
17. Harris AS (1950) Delayed development of ventricular ectopic rhythms following experimental coronary occlusion. Circulation 1: 1318-1328.
18. Clements-Jewery H, Hearse DJ, Curtis MJ (2007) Neutrophil ablation with antiserum does not protect against phase 2 ventricular arrhythmias in anaesthetised rats with myocardial infarction. Cardiovasc Res 73: 761-769.
19. Bernus O, Zemlin CW, Zaritsky RM, Mironov SF, Pertsov AM (2005) Alternating conduction in the ischaemic border zone as precursor of reentrant arrhythmias: a simulation study. Europace 7(Suppl 2): 93-104.
20. Cheema AN, Sheu K, Parker M, Kadish AH, Goldberger JJ (1998) Nonsustained ventricular tachycardia in the setting of acute myocardial infarction: tachycardia characteristics and their prognostic implications. Circulation 98: 2030-2036.
21. Remme CA, Wilde AA (2000) KATP channel openers, myocardial ischemia, and arrhythmias-should the electrophysiologist worry? Cardiovasc Drugs Ther 14: 17-22.
22. Wainwright CL, Parratt JR (1988) An antiarrhythmic effect of adenosine during myocardial ischaemia and reperfusion. Eur J Pharmacol 145: 183-194.
23. Yan GX, Joshi A, Guo D, Hlaing T, Martin J, et al. (2004) Phase 2 reentry as a trigger to initiate ventricular fibrillation during early acute myocardial ischemia. Circulation 110: 1036-1041.
24. Barrett TD, MacLeod BA, Walker MJ (1997) A model of myocardial ischemia for the simultaneous assessment of electrophysiological changes and arrhythmias in intact rabbits. J Pharmacol Toxicol Methods 37: 27-36.
25. Dilly SG, Lab MJ (1988) Electrophysiological alternans and restitution during acute regional ischaemia in myocardium of anaesthetized pig. J Physiol 402: 315-333.
26. Sedlis SP (1992) Mechanisms of ventricular arrhythmias in acute ischemia and reperfusion. Cardiovasc Clin 22: 3-18.
27. Gumina RJ, Daemmgen J, Gross GJ (2000) Inhibition of the Na(+)/H(+) exchanger attenuates phase 1b ischemic arrhythmias and reperfusion-induced ventricular fibrillation. Eur J Pharmacol 396: 119-124.
28. Russell DC, Lawrie JS, Riemersma RA, Oliver MF (1984) Mechanisms of phase 1a and 1b early ventricular arrhythmias during acute myocardial ischemia in the dog. Am J Cardiol 53: 307-312.
29. Parker KK, Lavelle JA, Taylor LK, Wang Z, Hansen DE (2004) Stretch-induced ventricular arrhythmias during acute ischemia and reperfusion. J Appl Physiol 97: 377-383.
30. Clements-Jewery H, Hearse DJ, Curtis MJ (2002) Independent contribution of catecholamines to arrhythmogenesis during evolving infarction in the isolated rat heart. Br J Pharmacol 135: 807-815.
31. Weiss SM, Benoist D, White E, Saint DA (2010) Riluzole protects against cardiac ischaemia and reperfusion damage via block of the persistent sodium current. British Journal of Pharmacology (in press) 160: 1072-1082.
32. Ju YK, Saint DA, Gage PW (1992) Effects of lignocaine and quinidine on the persistent sodium current in rat ventricular myocytes. Br J Pharmacol 107: 311-316.
33. Saint DA, Ju YK, Gage PW (1992) A persistent sodium current in rat ventricular myocytes. J Physiol 453: 219-231.
34. Ju YK, Saint DA, Gage PW (1996) Hypoxia increases persistent sodium current in rat ventricular myocytes. J Physiol 497(Pt 2): 337-347.
35. Satoh H, Mukai M, Urushida T, Katoh H, Terada H, et al. (2003) Importance of Ca2+ influx by Na+/Ca2+ exchange under normal and sodium-loaded conditions in mammalian ventricles. Mol Cell Biochem 242: 11-17.
36. Dekker LR, Rademaker H, Vermeulen JT, Opthof T, Coronel R, et al. (1998) Cellular uncoupling during ischemia in hypertrophied and failing rabbit ventricular myocardium: effects of preconditioning. Circulation 97: 1724-1730.
37. Riley MP, Marchlinski FE (2008) ECG clues for diagnosing ventricular tachycardia mechanism. J Cardiovasc Electrophysiol 19: 224-229.
38. Weiss SM, Einstein R, McCulloch RM (1993) A new method of fibrillation induction for implantable cardioverter-defibrillator testing. Journal of Clinical Engineering 18: 347-353.
39. Swerdlow CD, Shehata M, Chen PS (2007) Using the upper limit of vulnerability to assess defibrillation efficacy at implantation of ICDs. Pacing Clin Electrophysiol 30: 258-270.